| [1] |
MARIÑO Z, SCHILSKY ML. Wilson disease: Novel diagnostic and therapeutic approaches[J]. Semin Liver Dis, 2025, 45( 2): 221- 235. DOI: 10.1055/a-2460-8999. |
| [2] |
POUJOIS A, TROCELLO JM, DJEBRANI-OUSSEDIK N, et al. Exchangeable copper: A reflection of the neurological severity in Wilson’s disease[J]. Eur J Neurol, 2017, 24( 1): 154- 160. DOI: 10.1111/ene.13171. |
| [3] |
GUILLAUD O, BRUNET AS, MALLET I, et al. Relative exchangeable copper: A valuable tool for the diagnosis of Wilson disease[J]. Liver Int, 2018, 38( 2): 350- 357. DOI: 10.1111/liv.13520. |
| [4] |
MARIÑO Z, MOLERA-BUSOMS C, BADENAS C, et al. Benefits of using exchangeable copper and the ratio of exchangeable copper in a real-world cohort of patients with Wilson disease[J]. J Inherit Metab Dis, 2023, 46( 5): 982- 991. DOI: 10.1002/jimd.12639. |
| [5] |
European Association for the Study of the Liver. EASL-ERN clinical practice guidelines on Wilson’s disease[J]. J Hepatol, 2025, 82( 4): 690- 728. DOI: 10.1016/j.jhep.2024.11.007. |
| [6] |
SOLOVYEV N, ALA A, SCHILSKY M, et al. Biomedical copper speciation in relation to Wilson’s disease using strong anion exchange chromatography coupled to triple quadrupole inductively coupled plasma mass spectrometry[J]. Anal Chim Acta, 2020, 1098: 27- 36. DOI: 10.1016/j.aca.2019.11.033. |
| [7] |
BALKHI S EL, POUPON J, TROCELLO JM, et al. Determination of ultrafiltrable and exchangeable copper in plasma: Stability and reference values in healthy subjects[J]. Anal Bioanal Chem, 2009, 394( 5): 1477- 1484. DOI: 10.1007/s00216-009-2809-6. |
| [8] |
DEL CASTILLO BUSTO ME, CUELLO-NUNEZ S, WARD-DEITRICH C, et al. A fit-for-purpose copper speciation method for the determination of exchangeable copper relevant to Wilson’s disease[J]. Anal Bioanal Chem, 2022, 414( 1): 561- 573. DOI: 10.1007/s00216-021-03517-y. |
| [9] |
SCHILSKY ML, CZLONKOWSKA A, ZUIN M, et al. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease(CHELATE): A randomised, open-label, non-inferiority, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7( 12): 1092- 1102. DOI: 10.1016/S2468-1253(22)00270-9. |
| [10] |
HARRINGTON CF, CARPENTER G, COVERDALE JPC, et al. Accurate non-ceruloplasmin bound copper: A new biomarker for the assessment and monitoring of Wilson disease patients using HPLC coupled to ICP-MS/MS[J]. Clin Chem Lab Med, 2025, 63( 2): 320- 328. DOI: 10.1515/cclm-2024-0213. |
| [11] |
SANDAHL TD, HARRINGTON CF, KIRK FT, et al. Diagnosing Wilson disease in acute liver failure: Comparison of existing and experimental biomarkers[J]. Am J Gastroenterol, 2025. DOI: 10.14309/ajg.0000000000003654.[ Epub ahead of print] |
| [12] |
BITZER AC, FOX J, DAY PL, et al. Establishment of a labile bound copper reference interval in a healthy population via an inductively coupled plasma mass spectrometry dual filtration-based assay[J]. Arch Pathol Lab Med, 2024, 148( 7): 818- 827. DOI: 10.5858/arpa.2023-0259-OA. |
| [13] |
COLLINS CJ, YI F, DAYUHA R, et al. Direct measurement of ATP7B peptides is highly effective in the diagnosis of Wilson disease[J]. Gastroenterology, 2021, 160( 7): 2367- 2382. DOI: 10.1053/j.gastro.2021.02.052. |
| [14] |
ROWAN DJ, MANGALAPARTHI KK, SINGH S, et al. Metallothionein immunohistochemistry has high sensitivity and specificity for detection of Wilson disease[J]. Mod Pathol, 2022, 35( 7): 946- 955. DOI: 10.1038/s41379-021-01001-7. |
| [15] |
WIETHOFF H, MOHR I, FICHTNER A, et al. Metallothionein: A game changer in histopathological diagnosis of Wilson disease[J]. Histopathology, 2023, 83( 6): 936- 948. DOI: 10.1111/his.15041. |
| [16] |
CZŁONKOWSKA A, RODO M, WIERZCHOWSKA-CIOK A, et al. Accuracy of the radioactive copper incorporation test in the diagnosis of Wilson disease[J]. Liver Int, 2018, 38( 10): 1860- 1866. DOI: 10.1111/liv.13715. |
| [17] |
SANDAHL TD, GORMSEN LC, KJÆRGAARD K, et al. The pathophysiology of Wilson’s disease visualized: A human 64Cu PET study[J]. Hepatology, 2022, 75( 6): 1461- 1470. DOI: 10.1002/hep.32238. |
| [18] |
SU DN, ZHANG ZJ, ZHANG Z, et al. Distinctive pattern of metal deposition in neurologic Wilson disease: Insights from 7T susceptibility-weighted imaging[J]. Neurology, 2024, 102( 12): e209478. DOI: 10.1212/WNL.0000000000209478. |
| [19] |
LIANG C, BAI L, HOU W, et al. A multimodal neuroimaging and hepatic imaging analysis for hepatic-type and neurological-type Wilson’s disease[J]. Metab Target Organ Damage, 2025, 5( 4): 66- 82. DOI: 10.20517/mtod.2025.173. |
| [20] |
ESPINÓS C, FERENCI P. Are the new genetic tools for diagnosis of Wilson disease helpful in clinical practice?[J]. JHEP Rep, 2020, 2( 4): 100114. DOI: 10.1016/j.jhepr.2020.100114. |
| [21] |
MUNK DE, LUND LAURSEN T, TEICHER KIRK F, et al. Effect of oral zinc regimens on human hepatic copper content: A randomized intervention study[J]. Sci Rep, 2022, 12( 1): 14714. DOI: 10.1038/s41598-022-18872-8. |
| [22] |
SUMMER KH, LICHTMANNEGGER J, BANDOW N, et al. The biogenic methanobactin is an effective chelator for copper in a rat model for Wilson disease[J]. J Trace Elem Med Biol, 2011, 25( 1): 36- 41. DOI: 10.1016/j.jtemb.2010.12.002. |
| [23] |
BALASUBRAMANIAN R, ROSENZWEIG AC. Copper methanobactin: A molecule whose time has come[J]. Curr Opin Chem Biol, 2008, 12( 2): 245- 249. DOI: 10.1016/j.cbpa.2008.01.043. |
| [24] |
EINER C, MUNK DE, PARK E, et al. ARBM101(methanobactin SB2) drains excess liver copper via biliary excretion in Wilson’s disease rats[J]. Gastroenterology, 2023, 165( 1): 187- 200. DOI: 10.1053/j.gastro.2023.03.216. |
| [25] |
SANDAHL TD, LEE WM, ALA A, et al. WED-164 Interim safety results of the ongoing international phase I/II GATEWAY gene therapy trial with VTX-801 conducted in adult patients with Wilson disease[J]. J Hepatol, 2024, 80( Suppl 1): S714- S715. DOI: 10.1016/S0168-8278(24)02021-X. |
| [26] |
ZHANG J, CHEN H, BAO YC, et al. System pharmacology-based strategy to decode the synergistic mechanism of GanDouLing for Wilson’s disease[J]. Evid Based Complement Alternat Med, 2021, 2021: 1248920. DOI: 10.1155/2021/1248920. |
DownLoad: